Biotechnology advances

Using AI to design personalized cancer vaccines from tumor marker discovery to testing

Updated

Abstract

Generative artificial intelligence may enhance the design of neoantigen vaccines by optimizing candidate selection and vaccine constructs.

  • Current neoantigen vaccine strategies face challenges due to imperfect antigen prioritization and immune evasion.
  • Traditional computational models primarily rank existing mutant peptides based on HLA binding and antigen presentation features.
  • Generative AI offers a design-oriented approach that can explore and optimize biological sequences under specific constraints.
  • This technology could facilitate the development of multi-epitope and mRNA vaccine constructs that consider tumor-specific factors.
  • Bottlenecks in the field include limited datasets for validating immunogenicity and regulatory demands for transparency.
  • The clinical utility of generative AI in neoantigen vaccine design remains to be validated through future comparisons with established methods.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free